2023 ´ëÇѹ®¸Æ¾ÐÇ×ÁøÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö : 2023-07-01
±³À°ÀÏÀÚ : 2023-07-01
±³À°Àå¼Ò : ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº´ë°´ç
±³À°ÁÖÁ¦ : 2023 ´ëÇѹ®¸Æ¾ÐÇ×ÁøÁõ¿¬±¸È¸ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¹®¸Æ¾ÐÇ×ÁøÁõ ¿¬±¸È¸
´ã´çÀÚ : ´ëÇÑ°£ÇÐȸ
¿¬¶ôó : 02-707-0091
À̸ÞÀÏ : kasl@kams.or.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 70¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 0¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 07¿ù 01ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº´ë°´ç 13:30~13:45 Basic research in portal hypertension ÀÌ¿µ¼±(°í·ÁÀÇ´ë)
±³À°½Ã°£ 07¿ù 01ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº´ë°´ç 13:45~14:00 Clinical research in portal hypertension ½Å½Â°¢(°¡ÃµÀÇ´ë)
±³À°½Ã°£ 07¿ù 01ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº´ë°´ç 14:00~14:25 Personalized Antiviral Drug Selection in Chronic Hepatitis B Patients Using a Machine Learning Model: A Multinational Study Çã¹®Çà(¼¿ïÀÇ´ë)
±³À°½Ã°£ 07¿ù 01ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº´ë°´ç 14:25~14:50 AI application on liver cirrhosis ¼®±âÅÂ(ÇѸ²ÀÇ´ë)
±³À°½Ã°£ 07¿ù 01ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº´ë°´ç 15:05~15:30 Response-Guided Therapy with Cefotaxime, Ceftriaxone, or Ciprofloxacin for Spontaneous Bacterial Peritonitis ±èÅÂÇü(°í·ÁÀÇ´ë)
±³À°½Ã°£ 07¿ù 01ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº´ë°´ç 15:30~15:55 ¥â-blockers in advanced cirrhosis: More friend than enemy À±±âÅÂ(ºÎ»êÀÇ´ë)
Åä·Ð 07¿ù 01ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº´ë°´ç 15:55~16:05 Panel discussion ±è»ó±Õ, ±èÁ¤ÇÑ, Á¤½Â¿ø(¼øõÇâÀÇ´ë, °Ç±¹ÀÇ´ë, ¼øõÇâÀÇ´ë)
±³À°½Ã°£ 07¿ù 01ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº´ë°´ç 16:05~16:30 Immunological Clearance of Pathological Cells for Untreatable Liver Diseases ³²±âÈÆ(°í·ÁÀÇ´ë)
±³À°½Ã°£ 07¿ù 01ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº´ë°´ç 16:30~16:55 Association between serum tumor necrosis factor-¥á and sarcopenia in liver cirrhosis ÇÑÁö¿ø(°¡Å縯ÀÇ´ë)
Åä·Ð 07¿ù 01ÀÏ ¼øõÇâ´ëÇб³ ¼¿ïº´¿ø µ¿Àº´ë°´ç 16:55~17:05 Panel discussion ±è¹®¿µ, À庴±¹, ¹ÚÁ¤±æ(¿¬¼¼¿øÁÖÀÇ´ë, °è¸íÀÇ´ë, ¿µ³²ÀÇ´ë)